PRAMEF6

Across TCGA pan-cancer cohorts, PRAMEF6 RNA is linked to patient survival in 16 of 34 cancer types, making it the most broadly survival-associated PRAMEF6 data layer compared with 3 for mutation status.

The strongest signal is observed in small cell lung cancer (SCLC), where higher PRAMEF6 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PRAMEF6 expression acts as an unfavorable survival marker, although some lineages such as KIRP show a favorable association.

SCLC, BLCA, and UVM are the cancer types where PRAMEF6 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Tertile	II,III,IV	0.164	0.819	<.001	81	view →
BLCA	DFS	Tertile	All	0.094	0.594	.001	63	view →
UVM	OS	Tertile	All	0.213	0.696	.004	45	view →
THCA	DFS	Tertile	All	0.121	0.818	<.001	45	view →
KIRC	DFS	Tertile	II,III,IV	0.263	0.666	.008	42	view →
ESCA	OS	Tertile	IV	0.095	0.512	.008	36	view →
LUAD	OS	Tertile	All	0.248	0.700	<.001	36	view →
CESC	OS	Tertile	IV	0.091	0.593	<.001	36	view →
SARC	OS	Tertile	All	0.335	0.761	<.001	36	view →
LUSC	DFS	Tertile	All	0.213	0.647	.012	33	view →
LGG	DFS	Tertile	All	0.433	0.741	.017	21	view →
UCEC	OS	Tertile	All	0.849	0.931	.011	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 16 lineages.

PRAMEF6–SCLC (OS)

Open the SCLC breakdown →